Copenhagen, Denmark, 30 March 2026 – Draupnir Bio (“Draupnir”), a biotechnology company harnessing the natural machinery of the lysosome to develop oral, small molecule degraders of extracellular disease-causing proteins, today announces the publication of re…
Draupnirs novel SORTAC platform expands reach of targeted protein degradation to extracellular proteins, demonstrating in vitro and in vivo efficacy against difficult-to-drug targets
